TRPV2 and prostate carcinoma: Indeed, the progression of prostate cancer to the castration-resistant phenotype is characterized by de novo expression of TRPV2, and higher levels of TRPV2 transcripts are found in patients with metastatic cancer (stage M1) as compared to primary solid tumors (stage T2a and T2b) [71].